We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

58 hedge funds and large institutions have $440M invested in Crinetics Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

92% more capital invested

Capital invested by funds: $229M → $440M (+$211M)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

9.41% more ownership

Funds ownership: 62.95% → 72.36% (+9.4%)

5% less funds holding

Funds holding: 61 → 58 (-3)

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
24
Reduced
11
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$2.09M
2
OM
Opaleye Management
Massachusetts
+$1.13M
3
State Street
State Street
Massachusetts
+$387K
4
California Public Employees Retirement System
California Public Employees Retirement System
California
+$364K
5
Northern Trust
Northern Trust
Illinois
+$244K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.42M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.87M
3
Goldman Sachs
Goldman Sachs
New York
-$1.09M
4
Marshall Wace
Marshall Wace
United Kingdom
-$829K
5
Millennium Management
Millennium Management
New York
-$706K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$91.2M +$139K +7,320 +0.2%
PA
2
Perceptive Advisors
New York
$64.9M – – –
5VM
3
5AM Venture Management
California
$59.3M +$45M +2,362,286 New
O
4
OrbiMed
New York
$51.2M – – –
RCM
5
RA Capital Management
Massachusetts
$47M – – –
EAM
6
Eventide Asset Management
Massachusetts
$23.8M – – –
BlackRock
7
BlackRock
New York
$18.4M -$4.42M -231,947 -24%
Vanguard Group
8
Vanguard Group
Pennsylvania
$12.6M -$1.9K -100 -0%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$12.3M -$148K -7,788 -2%
OM
10
Opaleye Management
Massachusetts
$6.68M +$1.13M +59,100 +29%
State Street
11
State Street
Massachusetts
$5.68M +$387K +20,305 +10%
BCM
12
Burrage Capital Management
Massachusetts
$5.16M +$3.92M +205,726 New
PC
13
Polar Capital
United Kingdom
$5.02M +$2.09M +109,618 +121%
Victory Capital Management
14
Victory Capital Management
Texas
$4.9M -$364K -19,130 -9%
BBA
15
Baker Bros. Advisors
New York
$4.39M – – –
Northern Trust
16
Northern Trust
Illinois
$3.73M +$244K +12,793 +9%
NLVP
17
New Leaf Venture Partners
New York
$3.54M – – –
NHAS
18
Novo Holdings A/S
Denmark
$3.39M – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$3.22M +$128K +6,731 +6%
Charles Schwab
20
Charles Schwab
California
$1.33M +$37K +1,944 +4%
AA
21
ALPS Advisors
Colorado
$1.23M +$18.2K +955 +2%
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$906K -$308K -16,175 -31%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$899K +$22.5K +1,183 +3%
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$850K -$1.87M -98,135 -74%
N
25
Nuveen
North Carolina
$709K -$5.69K -299 -1%
1
2 3

CRNX Hedge Fund Activity: Q4 2019 in Review

58 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2019, worth a combined $440M — up 92% from $229M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CRNX positions and 7 closed out — a net gain of 2 holders — while 24 added to existing stakes and 11 trimmed.

The largest buyer was Polar Capital, adding an estimated $2.09M. The largest seller was BlackRock, cutting an estimated $4.42M.

  • 58 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2019, down from 61 in Q3 2019.
  • Funds reported $440M of Crinetics Pharmaceuticals stock for Q4 2019, up 92% quarter-over-quarter.
  • 9 funds opened new Crinetics Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of +2 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2019 was Polar Capital, an estimated $2.09M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $4.42M sold.

Based on aggregated 13F filings for Q4 2019.